HFA Premium Access

Association of Baseline Cardiac Biomarkers on Clinical Outcomes and Vericiguat Treatment Effect in Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA Trial

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Congress Presentation

About the speaker

Associate Professor Christopher DeFilippi

University of Maryland, Baltimore (United States of America)
2 presentations
0 follower

13 more presentations in this session

Omecamtiv Mecarbil in Patients with Severe Heart Failure: An Analysis from Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure (GALACTIC-HF)

Speaker: Professor G. Felker (Durham, US)

Thumbnail

Efficacy and Safety of Antithrombotic Strategies in Patients With Atrial Fibrillation and Recent ACS or PCI With and Without A History of Heart Failure: Insights From the AUGUSTUS Trial

Speaker: Doctor M. Fudim (Durham, US)

Thumbnail

Nurse Intervention for Less Chronic Heart Failure Study

Speaker: Professor S. Stewart (Adelaide, AU)

Thumbnail

Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial.

Speaker: Professor J. McMurray (Glasgow, GB)

Thumbnail

Telemedical Interventional Management in Heart Failure

Speaker: Professor F. Koehler (Berlin, DE)

Thumbnail

Access the full session

Clinical Trial Updates

Speakers: Associate Professor C. DeFilippi, Professor G. Felker, Doctor M. Fudim, Professor S. Stewart, Professor J. McMurray...
Thumbnail

About the event

Image

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb